He absolutely made the right decision. How many small pharma companies on the OTC, can or will claim a cash stream of 25 million, over the next seven years? They were looking at tons of dilution and likely years of large net losses, just to perhaps someday becoming profitable.
I don't think people realize the expense of going it alone, to manufacture and market a drug.
This will allow them the ability to focus on overseas approvals, the new ANDAs, and the patch. While offsetting those costs and expenses with the proceeds from this deal.
As soon as more details emerge about the partner and deal, we should recover, and then some.
Market Data 
Markets 
AI
